A multicenter real-world study on first-line treatment strategies for limited small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065309

Enrollment

Unknown

Registered

2022-11-01

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

chemotherap group:chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with small cell lung cancer; 2. It is expected to receive more than 2 cycles of systemic chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Non-small cell lung cancer; 2. Not receive systemic chemotherapy.

Design outcomes

Primary

Measure	Time frame
progression free survival;	—

Secondary

Measure	Time frame
overall survival;treatment-related toxicities;	—

Countries

China

Contacts

Public ContactWei Huang

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

alvinbird@126.com+86 531 67626162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026